Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dissemination of high-risk clones of extensively drug-resistant pseudomonas aeruginosa in Colombia

  • Correa, Adriana
  • Campo, Rosa del
  • Perenguez, Marcela
  • Blanco, Victor M.
  • Rodríguez-Baños, Mercedes
  • Pérez, Federico
  • Maya, Juan J.
  • Rojas, Laura
  • Cantón, Rafael
  • Arias, Cesar A.
  • Villegas, Maria V.
The ability of Pseudomonas aeruginosa to develop resistance to most antimicrobials represents an important clinical threat worldwide. We report the dissemination in several Colombian hospitals of two predominant lineages of extensively drug-resistant (XDR) carbapenemase-producing P. aeruginosa strains. These lineages belong to the high-risk clones sequence type 111 (ST111) and ST235 and harbor blaVIM-2 on a class 1 integron and blaKPC-2 on a Tn4401 transposon, respectively. Additionally, P. aeruginosa ST1492, a novel single-locus variant of ST111, was identified. Clonal dissemination and the presence of mobile genetic elements likely explain the successful spread of XDR P. aeruginosa strains in Colombia., This work was supported by Merck Sharp & Dohme, Janssen-Cilag SA, Pfizer SA, AstraZeneca Colombia SA, Merck Colombia, Novartis, Amarey Novamedical, Merck S.A, and bioMérieux Colombia, which help fund the Colombian Nosocomial Resistance Study Group (CNRSG). The research of Rafael Cantón at the Microbiology Department of Ramón y Cajal University Hospital is funded by the European Commission (grants R-GNOSIS-FP7-HEALTH-F3-2011-282512 and FP7-HEALTH-F3-2013-MON4STRAT-602906-2) and the Instituto de Salud Carlos III of Spain, cofinanced by the European Development Regional Fund (A Way to Achieve Europe program; Spanish Network for Research in Infectious Diseases grant REIPI RD12/0015).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates

  • Testa, Raymond
  • Cantón, Rafael
  • Giani, Tommaso
  • Morosini, María-Isabel
  • Nichols, Wright W.
  • Stefanike, Danuta
  • Rossolini, Gian Maria
  • Nordmann, Patrice
Recent clinical isolates of key Gram-negative and Gram-positive bacteria were collected in 2012 from hospitalised patients in medical centres in four European countries (France, Germany, Italy and Spain) and were tested using standard broth microdilution methodology to assess the impact of 4 mg/L avibactam on the in vitro activities of ceftazidime, ceftaroline and aztreonam. Against Enterobacteriaceae, addition of avibactam significantly enhanced the level of activity of these antimicrobials. MIC90 values (minimum inhibitory concentration that inhibits 90% of the isolates) of ceftazidime, ceftaroline and aztreonam for Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Enterobacter aerogenes, Citrobacter freundii and Morganella morganii were reduced up to 128-fold or greater when combined with avibactam. A two-fold reduction in the MIC90 of ceftazidime to 8 mg/L was noted in Pseudomonas aeruginosa isolates when combined with avibactam, whereas little effect of avibactam was noted on the MIC values of the test compounds when tested against Acinetobacter baumannii isolates. Avibactam had little effect on the excellent activity of ceftazidime, ceftaroline and aztreonam against Haemophilus influenzae. It had no impact on the in vitro activity of ceftazidime and ceftaroline against staphylococci and streptococci. This study demonstrates that addition of avibactam enhances the activities of ceftazidime, ceftaroline and aztreonam against Enterobacteriaceae and P. aeruginosa but not against A. baumannii., This study was funded by a grant from AstraZeneca and Actavis (formerly Forest Laboratories). The research of GMR is funded by the European Commission [grant EvoTar-FP7-HEALTH-F3-2011-2011-282004]. The research of HS at the Institute for Microbiology, Immunology and Hygiene (University Hospital of Cologne, Cologne, Germany) is supported by the German Center for Infection Research (DZIF) and the European Union, Directorate General for Research and Innovation through the Seventh Framework Program for Office of Research and Development [MagicBullet, grant agreement 278232]. The research of RC at the Microbiology Department of Ramón y Cajal University Hospital (Madrid, Spain) is funded by the European Commission [grants R-GNOSIS-FP7-HEALTH-F3-2011-282512, MON4STRAT-FP7-HEALTH-2013-INNOVATION-1-602906-2] and the Instituto de Salud Carlos III of Spain [FIS PI12/00734] and co-financed by the European Development Regional Fund [A Way to Achieve Europe program; Spanish Network for Research in Infectious Diseases grant REIPI RD12/0015].
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Antimicrobial resistance level and conjugation permissiveness shape plasmid distribution in clinical enterobacteria

  • Alonso-Del Valle, Aida
  • Toribio-Celestino, Laura
  • Quirant, Anna
  • Pi, Carles Tardio
  • DelaFuente, Javier
  • Cantón, Rafael
  • Rocha, Eduardo P. C.
  • Úbeda, Carles
  • Peña-Miller, Rafael
  • San Millán, Álvaro
This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas. 2314135120/-/DCSupplemental., Conjugative plasmids play a key role in the dissemination of antimicrobial resistance (AMR) genes across bacterial pathogens. AMR plasmids are widespread in clinical settings, but their distribution is not random, and certain associations between plasmids and bacterial clones are particularly successful. For example, the globally spread carbapenem resistance plasmid pOXA-48 can use a wide range of enterobacterial species as hosts, but it is usually associated with a small number of specific Klebsiella pneumoniae clones. These successful associations represent an important threat for hospitalized patients. However, knowledge remains limited about the factors determining AMR plasmid distribution in clinically relevant bacteria. Here, we combined in vitro and in vivo experimental approaches to analyze pOXA-48-associated AMR levels and conjugation dynamics in a collection of wild-type enterobacterial strains isolated from hospitalized patients. Our results revealed significant variability in these traits across different bacterial hosts, with Klebsiella spp. strains showing higher pOXA-48-mediated AMR and conjugation frequencies than Escherichia coli strains. Using experimentally determined parameters, we developed a simple mathematical model to interrogate the contribution of AMR levels and conjugation permissiveness to plasmid distribution in bacterial communities. The simulations revealed that a small subset of clones, combining high AMR levels and conjugation permissiveness, play a critical role in stabilizing the plasmid in different polyclonal microbial communities. These results help to explain the preferential association of plasmid pOXA-48 with K. pneumoniae clones in clinical settings. More generally, our study reveals that species- and strain-specific variability in plasmid-associated phenotypes shape AMR evolution in clinically relevant bacterial communities., This work was supported by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (ERC grant no. 757440-PLASREVOLUTION) and by the Instituto de Salud Carlos III (PI19/00749) cofunded by the European Development Regional Fund “A way to achieve Europe.” The R-GNOSIS project received financial support from the European Commission (grant no. R-GNOSIS-F P7-HEALTH- F3-2011-282512). C.U. was supported by a grant from MICINN (PID2020- 120292RB-I00)., Peer reviewed